JOHNSON & JOHNSON |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 154.2 USD | +1.02% |
|
+2.92% | -1.60% |
| May. 16 | Johnson & Johnson to Buy Proteologix For $850 Million in Cash | MT |
| May. 16 | Sector Update: Health Care Stocks Steady Premarket Thursday | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 383,911 | 414,310 | 450,358 | 461,849 | 377,317 | 371,302 | - | - |
| Enterprise Value (EV) 1 | 392,320 | 424,391 | 452,501 | 477,989 | 383,722 | 364,305 | 350,228 | 338,978 |
| P/E ratio | 25.9 x | 28.6 x | 21.9 x | 26.2 x | 11.4 x | 17.1 x | 16.2 x | 15.2 x |
| Yield | 2.57% | 2.53% | 2.45% | 2.52% | 3% | 3.13% | 3.27% | 3.41% |
| Capitalization / Revenue | 4.68 x | 5.02 x | 4.8 x | 4.86 x | 4.43 x | 4.2 x | 4.09 x | 3.96 x |
| EV / Revenue | 4.78 x | 5.14 x | 4.83 x | 5.03 x | 4.51 x | 4.12 x | 3.86 x | 3.61 x |
| EV / EBITDA | 14 x | 15.6 x | 12.4 x | 14.6 x | 12.6 x | 11.3 x | 10.6 x | 9.76 x |
| EV / FCF | 19.7 x | 21 x | 22.9 x | 27.8 x | 21 x | 15.7 x | 15.4 x | 14.4 x |
| FCF Yield | 5.08% | 4.76% | 4.37% | 3.6% | 4.76% | 6.39% | 6.51% | 6.96% |
| Price to Book | 6.46 x | 9.53 x | 6.08 x | 6.13 x | 5.84 x | 4.9 x | 4.43 x | 4 x |
| Nbr of stocks (in thousands) | 2,631,872 | 2,632,543 | 2,632,597 | 2,614,484 | 2,407,279 | 2,406,679 | - | - |
| Reference price 2 | 145.9 | 157.4 | 171.1 | 176.6 | 156.7 | 154.3 | 154.3 | 154.3 |
| Announcement Date | 1/22/20 | 1/26/21 | 1/25/22 | 1/24/23 | 1/23/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 82,059 | 82,584 | 93,775 | 94,943 | 85,159 | 88,371 | 90,781 | 93,854 |
| EBITDA 1 | 27,979 | 27,145 | 36,634 | 32,630 | 30,414 | 32,176 | 33,061 | 34,734 |
| EBIT 1 | 25,593 | 24,574 | 29,244 | 29,965 | 27,460 | 28,903 | 29,839 | 31,148 |
| Operating Margin | 31.19% | 29.76% | 31.19% | 31.56% | 32.25% | 32.71% | 32.87% | 33.19% |
| Earnings before Tax (EBT) 1 | 17,328 | 16,497 | 22,776 | 21,725 | 15,062 | 23,743 | 23,070 | 23,922 |
| Net income 1 | 15,119 | 14,714 | 20,878 | 17,941 | 35,153 | 22,039 | 23,092 | 24,466 |
| Net margin | 18.42% | 17.82% | 22.26% | 18.9% | 41.28% | 24.94% | 25.44% | 26.07% |
| EPS 2 | 5.630 | 5.510 | 7.810 | 6.730 | 13.72 | 9.003 | 9.523 | 10.13 |
| Free Cash Flow 1 | 19,918 | 20,189 | 19,758 | 17,185 | 18,248 | 23,276 | 22,812 | 23,581 |
| FCF margin | 24.27% | 24.45% | 21.07% | 18.1% | 21.43% | 26.34% | 25.13% | 25.12% |
| FCF Conversion (EBITDA) | 71.19% | 74.37% | 53.93% | 52.67% | 60% | 72.34% | 69% | 67.89% |
| FCF Conversion (Net income) | 131.74% | 137.21% | 94.64% | 95.79% | 51.91% | 105.61% | 98.79% | 96.38% |
| Dividend per Share 2 | 3.750 | 3.980 | 4.190 | 4.450 | 4.700 | 4.824 | 5.038 | 5.266 |
| Announcement Date | 1/22/20 | 1/26/21 | 1/25/22 | 1/24/23 | 1/23/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 24,804 | 23,426 | 24,020 | 23,791 | 23,706 | 24,746 | 25,530 | 21,351 | 21,395 | 21,383 | 22,325 | 22,202 | 22,382 | 21,890 | 22,954 |
| EBITDA 1 | 7,939 | 9,305 | 9,011 | 9,299 | 7,804 | 8,880 | 8,912 | 8,071 | 6,333 | 7,973 | 8,376 | 8,289 | 7,696 | 8,208 | - |
| EBIT 1 | 6,096 | 7,536 | 7,267 | 7,614 | 7,093 | 8,204 | 8,189 | 7,374 | 5,638 | 7,236 | 7,403 | 7,410 | 6,893 | 7,451 | 7,716 |
| Operating Margin | 24.58% | 32.17% | 30.25% | 32% | 29.92% | 33.15% | 32.08% | 34.54% | 26.35% | 33.84% | 33.16% | 33.38% | 30.8% | 34.04% | 33.62% |
| Earnings before Tax (EBT) 1 | 4,836 | 5,862 | 5,840 | 5,822 | 4,201 | -737 | 6,762 | 5,217 | 4,826 | 6,440 | 6,710 | 6,358 | 5,878 | - | - |
| Net income 1 | 4,736 | - | - | 4,458 | 3,520 | -68 | 5,144 | 26,028 | 4,049 | 5,354 | 5,446 | 5,200 | 7,348 | 5,471 | 5,794 |
| Net margin | 19.09% | - | - | 18.74% | 14.85% | -0.27% | 20.15% | 121.91% | 18.92% | 25.04% | 24.39% | 23.42% | 32.83% | 24.99% | 25.24% |
| EPS 2 | 1.770 | 1.930 | 1.800 | 1.680 | 1.330 | -0.0300 | 1.960 | 10.21 | 1.670 | 2.200 | 2.202 | 2.212 | 2.710 | 2.294 | 2.391 |
| Dividend per Share 2 | 1.060 | 1.060 | 1.130 | 1.130 | 1.130 | 1.130 | 1.190 | 1.190 | 1.190 | 1.190 | 1.225 | 1.205 | 1.225 | 1.221 | 1.221 |
| Announcement Date | 1/25/22 | 4/19/22 | 7/19/22 | 10/18/22 | 1/24/23 | 4/18/23 | 7/20/23 | 10/17/23 | 1/23/24 | 4/16/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 8,409 | 10,081 | 2,143 | 16,140 | 6,405 | - | - | - |
| Net Cash position 1 | - | - | - | - | - | 6,997 | 21,075 | 32,324 |
| Leverage (Debt/EBITDA) | 0.3005 x | 0.3714 x | 0.0585 x | 0.4946 x | 0.2106 x | - | - | - |
| Free Cash Flow 1 | 19,918 | 20,189 | 19,758 | 17,185 | 18,248 | 23,276 | 22,812 | 23,581 |
| ROE (net income / shareholders' equity) | 39.1% | 34.9% | 38.2% | 23.8% | 34.9% | 35.2% | 33.1% | 31.5% |
| ROA (Net income/ Total Assets) | 15% | 12.9% | 14.7% | 9.71% | 14.3% | 13.9% | 14% | 14.3% |
| Assets 1 | 100,753 | 114,174 | 142,233 | 184,698 | 245,525 | 158,438 | 165,151 | 171,052 |
| Book Value Per Share 2 | 22.60 | 16.50 | 28.20 | 28.80 | 26.90 | 31.50 | 34.80 | 38.60 |
| Cash Flow per Share 2 | 8.720 | 8.810 | 8.750 | 7.960 | 8.900 | 11.10 | 11.10 | 13.40 |
| Capex 1 | 3,498 | 3,347 | 3,652 | 4,009 | 4,543 | 4,021 | 4,035 | 4,125 |
| Capex / Sales | 4.26% | 4.05% | 3.89% | 4.22% | 5.33% | 4.55% | 4.44% | 4.39% |
| Announcement Date | 1/22/20 | 1/26/21 | 1/25/22 | 1/24/23 | 1/23/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
154.3
USD
Average target price
173.3
USD
Spread / Average Target
+12.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.60% | 371B | |
| +32.36% | 694B | |
| +29.81% | 593B | |
| +20.07% | 331B | |
| +6.04% | 290B | |
| +14.42% | 239B | |
| +10.37% | 209B | |
| -3.11% | 209B | |
| +9.27% | 169B | |
| +0.45% | 164B |
- Stock Market
- Equities
- JNJ Stock
- Financials Johnson & Johnson
